Cargando…

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study

A vaccine booster to maintain high antibody levels and provide effective protection against COVID-19 has been recommended. However, little is known about the safety of a booster for different vaccines. We conducted a parallel controlled prospective study to compare the safety of a booster usingfour...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhi-Qiang, Wu, Jiang-Nan, Huang, Rong-Dong, Xie, Fang-Qin, Li, Jun-Rong, Zheng, Kui-Cheng, Zhang, Dong-Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024909/ https://www.ncbi.nlm.nih.gov/pubmed/35455370 http://dx.doi.org/10.3390/vaccines10040622

Ejemplares similares

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
por: Farahmand, Behrokh, et al.
Publicado: (2023)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis
por: Xu, Jiawei, et al.
Publicado: (2019)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
por: Jara, Alejandro, et al.
Publicado: (2022)

Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains
por: Xiao, Chanchan, et al.
Publicado: (2022)

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
por: Tung, Tao-Hsin, et al.
Publicado: (2022)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial
por: Ahi, Mohammadreza, et al.
Publicado: (2022)

Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice
por: Luan, Ning, et al.
Publicado: (2023)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human
por: Zhang, Yuwei, et al.
Publicado: (2022)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

The Duration of Intestinal Immunity After an Inactivated Poliovirus Vaccine Booster Dose in Children Immunized With Oral Vaccine: A Randomized Controlled Trial
por: John, Jacob, et al.
Publicado: (2017)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
por: Intapiboon, Porntip, et al.
Publicado: (2021)

COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
por: Huang, Qingrui, et al.
Publicado: (2022)

Field Trial of Primary and Booster Dose of Inactivated Vaccine Against Bovine Respiratory Bacteria in Young Holstein Calves
por: Mori, Kazusa, et al.
Publicado: (2020)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study
por: Wen, Gui-Ping, et al.
Publicado: (2023)

Booster or additional vaccination doses in patients vaccinated against COVID-19
por: García-Botella, Alejandra, et al.
Publicado: (2021)

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
por: Chen, Qian, et al.
Publicado: (2023)

Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy
por: Dick, Aharon, et al.
Publicado: (2022)

Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial
por: Chang, Yu-Tzu, et al.
Publicado: (2021)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Myopericarditis After COVID-19 Booster Dose Vaccination
por: Sharff, Katie A., et al.
Publicado: (2022)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_015tq5h4vpp4qvl6enqs5d81fb